AAM
MACK

Azzad Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Azzad Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,200
Closed -$36.5K – 360
2019
Q4 		$36.5K Buy
+11,200
New +$44.9K ﹤0.01% 354

Other funds holding MACK

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
LPIC
LeJeune Puetz Investment Counsel Traverse City, Michigan $279M AUM 4.39% 1-Year Est. Return

Azzad Asset Management's MACK Position: Q1 2020 in Review

Azzad Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2020, closing a stake of 11,200 shares — an estimated $36.5K sold.

Azzad Asset Management first reported a position in MACK in Q4 2019 and held it in 1 quarter. The position peaked at $36.5K in Q4 2019. 37 funds tracked by Wall St. Rank hold MACK as of Q1 2020.

  • Azzad Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Azzad Asset Management sold 11,200 Merrimack Pharmaceuticals, Inc. shares in Q1 2020, an estimated $36.5K.
  • Azzad Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Azzad Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $36.5K in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2020.

Based on Azzad Asset Management's 13F filing for Q1 2020, filed 1 Apr 2024.